Gubra today announced the appointment of Adam Lange as the company’s new Head of Investor Relations, effective June 1, 2026.
Adam Lange joins Gubra with significant experience across investor relations, finance, and business development functions in pharmaceutical and biotech companies of different stages and sizes, including Novo Nordisk, Zealand Pharma, and UNION therapeutics, with exposure to obesity and metabolic disease, immunology, and inflammation. Most recently, he served as Head of Investor Relations at Zealand Pharma.
“We are very pleased to welcome Adam to Gubra,” said Kristian Borbos, Chief Financial Officer of Gubra. “Adam brings a strong track record within investor relations and broad experience from pharmaceutical and biotech companies in therapeutic areas of strategic importance to Gubra. His experience will be highly valuable as we continue to strengthen our position in the market and engage with the investment community around Gubra’s long-term strategy and growth opportunities.”
Adam Lange commented:
“I am excited to join Gubra at an important and dynamic stage of the company’s journey. Gubra has established a strong scientific platform validated by multiple partnerships and a unique business model around its Biotech unit, pre-clinical CRO services, and the newly launched Ventures arm. I look forward to working closely with management, investors, and analysts to communicate the company’s progress and long-term value creation potential.”